The DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.
Adverse Events Associated with Testosterone Administration
Open accessAbstract
BACKGROUND: Testosterone supplementation has been shown to increase muscle mass and strength in healthy older men. The safety and efficacy of testosterone treatment in older men who have limitations in mobility have not been studied. METHODS: Community-dwelling men, 65 years of age or older, with limitations in mobility and a total serum testosterone level of 100 to 350 ng per deciliter (3.5 to 12.1 nmol per liter) or a free serum testosterone level of less than 50 pg per milliliter (173 pmol per liter) were randomly assigned to receive placebo gel or testosterone gel, to be applied daily for 6 months. Adverse events were categorized with the use of the Medical Dictionary for Regulatory Activities classification. The data and safety monitoring board recommended that the trial be discontinued early because there was a significantly higher rate of adverse cardiovascular events in the testosterone group than in the placebo group. RESULTS: A total of 209 men (mean age, 74 years) were enrolled at the time the trial was terminated. At baseline, there was a high prevalence of hypertension, diabetes, hyperlipidemia, and obesity among the participants. During the course of the study, the testosterone group had higher rates of cardiac, respiratory, and dermatologic events than did the placebo group. A total of 23 subjects in the testosterone group, as compared with 5 in the placebo group, had cardiovascular-related adverse events. The relative risk of a cardiovascular-related adverse event remained constant throughout the 6-month treatment period. As compared with the placebo group, the testosterone group had significantly greater improvements in leg-press and chest-press strength and in stair climbing while carrying a load. CONCLUSIONS: In this population of older men with limitations in mobility and a high prevalence of chronic disease, the application of a testosterone gel was associated with an increased risk of cardiovascular adverse events. The small size of the trial and the unique population prevent broader inferences from being made about the safety of testosterone therapy. (ClinicalTrials.gov number, NCT00240981.)
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Current evidence consistently shows that untreated low testosterone levels are associated with an increased risk of MACE”
From Evaluation and Management of Testosterone Deficiency: AUA Guideline (2018) · cites this paper as [41]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Nevertheless, T supplementation is not without risk and could potentially be harmful concerning cardiovascular risk in the elderly [248].”
From Role of sex hormone-binding globulin in the free hormone hypothesis and the relevance of free testosterone in androgen physiology (2022) · cites this paper as [248]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Several studies have previously reported that testosterone levels are linked to a variety of conditions and diseases, such as cardiovascular disease, type-2 diabetes, the metabolic syndrome, erectile dysfunction, depression, obesity, stroke and osteoporosis. 1-7”
From Cigarette smoking has a positive and independent effect on testosterone levels (2013) · cites this paper as [7]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“studies that measure cardiovascular benefit or harm in men on testosterone therapy have returned inconsistent and controversial results.”
From Evaluation and Management of Testosterone Deficiency: AUA Guideline (2018) · cites this paper as [41]
The cited source says what the claim attributes to it.
In the citing paper
“the current scientific literature does not definitively demonstrate that testosterone therapy increases the risk of MACE.”
From Evaluation and Management of Testosterone Deficiency: AUA Guideline (2018) · cites this paper as [41]
The cited source says what the claim attributes to it.
In the citing paper
“and that testosterone administration can increase the risk of cardiovascular adverse events as well. 7”
From Cigarette smoking has a positive and independent effect on testosterone levels (2013) · cites this paper as [7]
In the citing paper
“Low vitamin D levels have been associated with frailty (133)”
From Frailty in elderly people (2013) · cites this paper as [133]
In the citing paper
“Additionally, testosterone replacement is not without potential risks, including increased respiratory disorders (eg, cough, shortness of breath, asthma or chronic obstructive pulmonary disease (COPD) exacerbation, sleep apnoea) and skin and subcutaneous tissue disorders (eg, application site reactions, itching, erythema, foot ulcers, and increased hair growth).84”
From Age-related and disease-related muscle loss: The effect of diabetes, obesity, and other diseases (2014) · cites this paper as [84]
In the citing paper
“preventing an age-related decline in hormones by exogenous replacement is associated with increased risk for adverse effects in older adults.11-13”
From Hormonal and Metabolic Changes of Aging and the Influence of Lifestyle Modifications (2021) · cites this paper as [13]
In the citing paper
“Unfortunately, hormone replacement therapy is not a panacea, as it often results in various adverse events which outweigh its potential health benefits.”
From Hormonal and Metabolic Changes of Aging and the Influence of Lifestyle Modifications (2021) · cites this paper as [13]
In the citing paper
“Some of the risks associated with T therapy include exacerbation of prostate cancer, cardiovascular-related events, hepatotoxicity, erythrocytosis, sleep apnea, and dermatological issues.12, 13”
From Hormonal and Metabolic Changes of Aging and the Influence of Lifestyle Modifications (2021) · cites this paper as [13]
In the citing paper
“Serum hepcidin was measured by enzyme-linked immunosorbent assay (Intrinsic Life Sciences) with sensitivity of 5 ng/mL, interassay coefficient of variation 12%, and range 29-254 ng/ mL in men (12,15).”
From Testosterone induces erythrocytosis via increased erythropoietin and suppressed hepcidin: evidence for a new erythropoietin/hemoglobin set point (2014) · cites this paper as [12]
In the citing paper
“We have reported that administration of supraphysiologic doses of testosterone in healthy men suppresses the iron regulatory peptide hepcidin while EPO levels remained unchanged after 20 weeks of treatment (12).”
From Testosterone induces erythrocytosis via increased erythropoietin and suppressed hepcidin: evidence for a new erythropoietin/hemoglobin set point (2014) · cites this paper as [12]
In the citing paper
“We also show that testosterone administration is associated with lower hepcidin levels in older men with mobility limitation and high burden of chronic diseases, confirming our previous observations in healthy younger and older men and demonstrating a similar magnitude of hepcidin suppression (12).”
From Testosterone induces erythrocytosis via increased erythropoietin and suppressed hepcidin: evidence for a new erythropoietin/hemoglobin set point (2014) · cites this paper as [12]
In the citing paper
“Changes in fat mass, lean body mass, and muscle strength occur within 12–16 weeks, stabilize at 6–12 months, but can marginally continue over years.”
From Onset of effects of testosterone treatment and time span until maximum effects are achieved (2011) · cites this paper as [16]
In the citing paper
“It can be concluded that the effects of testosterone on muscle strength are demonstrable after 12–20 weeks and that depending on the achieved testosterone levels, the maximum effects are attained after 6 or 12 months.”
From Onset of effects of testosterone treatment and time span until maximum effects are achieved (2011) · cites this paper as [16]
In the citing paper
“Another study using high doses of testosterone gel (starting dose 100 mg/day with possible up-titration to 150 mg/day) observed significant increases in leg press strength, chest press strength, and stair climbing power with a load within 6 months (16).”
From Onset of effects of testosterone treatment and time span until maximum effects are achieved (2011) · cites this paper as [16]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lower-extremity function in persons over the age of 70 years as a predictor of subsequent disability
Guralnik, J. M., Ferrucci, L., Simonsick, E. M., Salive, M. E., & Wallace, R. B. (1995) · New England Journal of Medicine · doi:10.1056/nejm199503023320902 · Cited by 4,083
Bhasin, S., Cunningham, G. R., Hayes, F. J., Matsumoto, A. M., Snyder, P. J., Swerdloff, R. S., & Montori, V. M. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2354 · Cited by 1,954
Self-citationThe effects of supraphysiologic doses of testosterone on muscle size and strength in normal men
Bhasin, S., Storer, T. W., Berman, N., Callegari, C., Clevenger, B., Phillips, J., Bunnell, T. J., Tricker, R., Shirazi, A., & Casaburi, R. (1996) · New England Journal of Medicine · doi:10.1056/nejm199607043350101 · Cited by 1,659
Self-citationFried, L. P. (1998) · JAMA · doi:10.1001/jama.279.8.585 · Cited by 1,107
Newman, A. B., Simonsick, E. M., Naydeck, B. L., Boudreau, R. M., Kritchevsky, S. B., Nevitt, M. C., Pahor, M., Satterfield, S., Brach, J. S., Studenski, S. A., et al. (2006) · JAMA · doi:10.1001/jama.295.17.2018 · Cited by 934
Testosterone Replacement in Older Hypogonadal Men: A 12-Month Randomized Controlled Trial
Sih, R., Morley, J. E., Kaiser, F. E., Perry, H. M., Patrick, P., & Ross, C. (1997) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.82.6.3988 · Cited by 920
Associations of Subclinical Cardiovascular Disease With Frailty
Newman, A. B., Gottdiener, J. S., McBurnie, M. A., Hirsch, C. H., Kop, W. J., Tracy, R. P., Walston, J. D., & Fried, L. P. (2001) · The Journals of Gerontology Series A · doi:10.1093/gerona/56.3.m158 · Cited by 813
Predictors of skeletal muscle mass in elderly men and women
Baumgartner, R. N., Waters, D. L., Gallagher, D., Morley, J. E., & Garry, P. J. (1999) · Mechanisms of Ageing and Development · doi:10.1016/s0047-6374(98)00130-4 · Cited by 809
Low Serum Testosterone and Mortality in Older Men
Laughlin, G. A., Barrett-Connor, E., & Bergstrom, J. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-1792 · Cited by 798
Effects of testosterone supplementation in the aging male
Tenover, J. S. (1992) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.75.4.1092 · Cited by 768
Flagged first, then by citations
Research works printed but not linked: 1
- 10.1210/jc.82.6.1661 · DOI
Cited by
Sorted by citations
Items 801–900 of 1,000
Casaburi, R. H., Nakata, J., Bistrong, L., Torres, E., Rambod, M., & Pórszász, J. (2015) · Chronic Obstructive Pulmonary Diseases Journal of the COPD Foundation · doi:10.15326/jcopdf.3.1.2015.0128 · Cited by 12
Monitoring testosterone replacement therapy with transdermal gel: when and how?
Sansone, A., Sansone, M., Selleri, R., Schiavo, A., Gianfrilli, D., Pozza, C., Zitzmann, M., Lenzi, A., & Romanelli, F. (2019) · Journal of Endocrinological Investigation · doi:10.1007/s40618-019-01082-x · Cited by 13
Clinical pharmacists and basic scientists: do patients and physicians need this collaboration?
Zargarzadeh, A. H., Jacob, S., Klotz, R. S., & Khasawneh, F. T. (2011) · International Journal of Clinical Pharmacy · doi:10.1007/s11096-011-9562-6 · Cited by 12
Zwetsloot, K. A., Shanely, R. A., Godwin, J. S., & Hodgman, C. F. (2021) · Frontiers in Rehabilitation Sciences · doi:10.3389/fresc.2021.757789 · Cited by 11
Blackwell, K., Blackwell, M., & Blackwell, T. (2023) · Current Cardiology Reports · doi:10.1007/s11886-023-01935-1 · Cited by 12
Exceeding the Limits with Nutraceuticals: Looking Towards Parkinson’s Disease and Frailty
Montanari, M., Mercuri, N. B., & Martella, G. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms26010122 · Cited by 12
Wang, H., Zhou, Z., Liu, X., & Chen, Y. (2025) · Nutrition & Metabolism · doi:10.1186/s12986-025-00907-2 · Cited by 11
Lee, S. Y., Kim, W. D., Park, H., Park, S. C., Kim, I. K., & Chung, S. G. (2015) · Journal of Cachexia Sarcopenia and Muscle · doi:10.1002/jcsm.12074 · Cited by 11
Late-onset male hypogonadism: clinical and laboratory evaluation
Ho, C. K. M., & Beckett, G. J. (2011) · Journal of Clinical Pathology · doi:10.1136/jcp.2010.076968 · Cited by 11
Vulnerability to diabetes in Chinese: an age–period–cohort analysis
Wong, I. O. L., Cowling, B. J., & Schooling, C. M. (2014) · Annals of Epidemiology · doi:10.1016/j.annepidem.2014.10.010 · Cited by 11
Myths and truths of growth hormone and testosterone therapy in heart failure
Nguyen, C. T., Aaronson, A. J., Morrissey, R. P., Agarwal, M., Willix, R., & Schwarz, E. R. (2011) · Expert Review of Cardiovascular Therapy · doi:10.1586/erc.11.25 · Cited by 11
Chasland, L. C., Knuiman, M. W., Divitini, M., Chan, Y. X., Handelsman, D. J., Naylor, L. H., GREEN, D. J., & Yeap, B. B. (2017) · Clinical Endocrinology · doi:10.1111/cen.13407 · Cited by 11
Emerging Interventions for Elderly Patients—The Promise of Regenerative Medicine
Miller, R. R., & Roubenoff, R. (2018) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1272 · Cited by 11
Handelsman, D. J. (2020) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.5080 · Cited by 11
Xu, Z., Chen, X., Zhou, H., Ren, C., Wang, Q., Pan, Y., Liu, L., & Liu, X. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1335146 · Cited by 11
Cardio-oncology in advanced prostate cancer
Chen, K., Wong, T. H., Tan, Y. G., Tay, K. J., Tan, W. C., Chan, J., Ho, H. S. S., Cheng, C. W. S., Teoh, J. Y., Chiu, P. K., et al. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1386597 · Cited by 11
Why Do We Need a Trial on the Effects of Testosterone Therapy in Older Men?
Cook, N. L., & Romashkan, S. (2010) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2010.217 · Cited by 11
Testosterone replacement therapy for late-onset hypogonadism: current trends in Korea
Ko, Y. H., & Kim, J. J. (2011) · Asian Journal of Andrology · doi:10.1038/aja.2010.124 · Cited by 11
Wu, B. W., Berger, M., Sum, J. C., Hatch, G. F. R., & Schroeder, E. T. (2014) · BMC Surgery · doi:10.1186/1471-2482-14-102 · Cited by 11
Ruige, J. B., Rietzschel, E. R., Buyzere, M. D., Bekaert, S., Segers, P., Bacquer, D. D., Backer, G. D., Gillebert, T. C., Kaufman, J., & on behalf of the Asklepios investigators (2011) · International Journal of Andrology · doi:10.1111/j.1365-2605.2011.01191.x · Cited by 11
Does long-term androgen deficiency lead to metabolic syndrome in middle-aged rats?
Borbélyová, V., Renczés, E., Bábíčková, J., Tóthová, Ľ., Kačmárová, M., Uličná, O., Ostatníková, D., Hodosy, J., & Celec, P. (2017) · Experimental Gerontology · doi:10.1016/j.exger.2017.08.016 · Cited by 11
Frailty in Trauma Patients: An Emerging Geriatric Syndrome
Khan, M., & Joseph, B. A. (2017) · Current Surgery Reports · doi:10.1007/s40137-017-0193-2 · Cited by 11
Injection testosterone and adverse cardiovascular events: A case‐crossover analysis
Layton, J. B., Li, D., Meier, C. R., Sharpless, J. L., Stürmer, T., & Brookhart, M. A. (2018) · Clinical Endocrinology · doi:10.1111/cen.13574 · Cited by 11
The Role of Testosterone in Patients With Heart Failure: A Systematic Review
Park, S., Gale, S. E., & Watson, K. (2020) · Cardiology in Review · doi:10.1097/crd.0000000000000350 · Cited by 11
Hypogonadism and cancer survivorship
Faw, C. A., & Brannigan, R. E. (2020) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000583 · Cited by 11
Pharmacologic Interventions for Fracture Risk Reduction in the Oldest Old: What Is the Evidence?
Sfeir, J. G., & Pignolo, R. J. (2021) · JBMR Plus · doi:10.1002/jbm4.10538 · Cited by 11
Osteoporosis in Men: What has Changed?
Adler, R. A. (2010) · Current Osteoporosis Reports · doi:10.1007/s11914-010-0039-7 · Cited by 11
Lipid Effects of Endocrine Medications
Mihailescu, D. V., Vora, A., & Mazzone, T. (2010) · Current Atherosclerosis Reports · doi:10.1007/s11883-010-0146-z · Cited by 12
Improvement of endothelial function following initiation of testosterone replacement therapy
Shoskes, D. A., Tucky, B. H., & Polackwich, A. S. (2016) · Translational Andrology and Urology · doi:10.21037/tau.2016.08.04 · Cited by 11
Drugs of Muscle Wasting and Their Therapeutic Targets
Sakuma, K., & Yamaguchi, A. (2018) · Advances in experimental medicine and biology · doi:10.1007/978-981-13-1435-3_21 · Cited by 12
Swerdloff, R. S., & Wang, C. (2020) · Andrology · doi:10.1111/andr.12901 · Cited by 11
Braga, M. A. P., Rivera, A., Marinheiro, G., Felix, N. S., Carvalho, P. E. P., Gewehr, D. M., Teixeira, L., Clemente, M. R. C., Reis, P. C. A., de Amorim, L. G. C. R., et al. (2025) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-025-00737-w · Cited by 10
Does Testosterone Increase the Risk of a Cardiovascular Event?
Seftel, A. D., & Morgentaler, A. (2014) · The Journal of Urology · doi:10.1016/j.juro.2014.04.021 · Cited by 10
Kava, B. (2014) · Current Urology Reports · doi:10.1007/s11934-014-0422-5 · Cited by 10
Maggio, M. G., Nicolini, F., Cattabiani, C., Beghi, C., Gherli, T., Schwartz, R. S., Valenti, G., & Ceda, G. P. (2012) · Contemporary Clinical Trials · doi:10.1016/j.cct.2012.02.019 · Cited by 10
Trials of testosterone replacement reporting cardiovascular adverse events
Basaria, S. S., & Gagliano‐Jucá, T. (2018) · Asian Journal of Andrology · doi:10.4103/aja.aja_28_17 · Cited by 10
Self-citationRisks of Serious Injury with Testosterone Treatment
Yarnell, C. J., Thiruchelvam, D., & Redelmeier, D. A. (2020) · The American Journal of Medicine · doi:10.1016/j.amjmed.2020.07.037 · Cited by 10
Panhuis, W. I. H., Schönke, M., Siebeler, R., Banen, D., Pronk, A. C. M., Streefland, T. C. M., Afkir, S., Sips, H. C. M., Kroon, J., Rensen, P. C. N., et al. (2023) · The FASEB Journal · doi:10.1096/fj.202201586r · Cited by 11
Menakuru, S. R., Atta, M., Dhillon, V. S., & Salih, A. M. (2023) · Hematology Reports · doi:10.3390/hematolrep15020029 · Cited by 10
Testosterone and type 2 diabetes prevention: translational lessons from the T4DM study
Wittert, G., Grossmann, M., Yeap, B. B., & Handelsman, D. J. (2023) · Journal of Endocrinology · doi:10.1530/joe-22-0223 · Cited by 10
Review of guidelines on diagnosis and treatment of testosterone deficiency
Swerdloff, R. S., & Wang, C. C. L. (2012) · Cambridge University Press eBooks · doi:10.1017/cbo9781139003353.019 · Cited by 10
Vutthasathien, P., & Wattanapermpool, J. (2015) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00224.2015 · Cited by 10
Vellas, B. J., Fielding, R. A., Miller, R. R., Rolland, Y., Bhasin, S., Magaziner, J. S., & Bischoff-Ferrari, H. A. (2014) · The Journal of Frailty & Aging · doi:10.14283/jfa.2014.24 · Cited by 11
Self-citationBlood donation and testosterone replacement therapy
Chin-Yee, B. H., Lazo‐Langner, A., Butler‐Foster, T., Hsia, C. C., & Chin-Yee, I. H. (2017) · Transfusion · doi:10.1111/trf.13970 · Cited by 10
Chrysant, S. G., & Chrysant, G. S. (2018) · Hospital Practice · doi:10.1080/21548331.2018.1445405 · Cited by 11
Seara, F. D. A. C., Barbosa, R. A. Q., Santos, M. V. N., Domingos, A. E., Monnerat, G., Carvalho, A. B., Olivares, E. L., Mill, J. G., Nascimento, J. H. M., & de Carvalho, A. C. C. (2019) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2019.03.012 · Cited by 10
Woo, E. C.-H., & Rodis, B. (2019) · Annals of the Academy of Medicine Singapore · doi:10.47102/annals-acadmedsg.v48n11p363 · Cited by 10
Therapeutic Phlebotomy for Testosterone-Induced Polycythemia
Buren, N. L. V., Hove, A. J., French, T. A., & Gorlin, J. B. (2020) · American Journal of Clinical Pathology · doi:10.1093/ajcp/aqaa019 · Cited by 10
Testosterone therapy in hypogonadal patients and the associated risks of cardiovascular events
Kharaba, Z. J., Buabeid, M. A., Ibrahim, N. A., Jirjees, F., Al-Obaidi, H. J., Kaddaha, A., Khajehkarimoddini, L., & Alfoteih, Y. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110423 · Cited by 10
de Araújo, A. B., Chiu, G. R., Christian, J. B., Kim, H. Y., Evans, W. J., & Clark, R. V. (2013) · Clinical Endocrinology · doi:10.1111/cen.12212 · Cited by 10
Pospíšilová, H., Vaňková, M., Hill, M., Meloun, M., Bendlová, B., Dušková, M., & Stárka, L. (2012) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2012.02.005 · Cited by 10
Perspectives for metabolomics in testosterone replacement therapy
Haring, R. (2012) · Journal of Endocrinology · doi:10.1530/joe-12-0119 · Cited by 10
Androgen Deficiency in Heart Failure
Güder, G., Allolio, B., Angermann, C. E., & Störk, S. (2011) · Current Heart Failure Reports · doi:10.1007/s11897-011-0053-9 · Cited by 10
Diagnosis and treatment of hypogonadism in older men: proceed with caution
Grossmann, M. (2010) · Asian Journal of Andrology · doi:10.1038/aja.2010.107 · Cited by 10
Surgical and pharmacological reassignment: influence on transsexual cardiovascular risk profile
Ciccone, M. M., Loverro, G., Scicchitano, P., Loverro, M., Ricci, G., Scaramuzzi, F., Gesualdo, M., Zito, A., Campagna, M., Moncelli, M., et al. (2017) · Internal Medicine Journal · doi:10.1111/imj.13597 · Cited by 10
Sigalos, J. T., Pastuszak, A. W., & Khera, M. (2017) · Medical Clinics of North America · doi:10.1016/j.mcna.2017.10.011 · Cited by 10
Curley, M. K., Gonzalez, Z. N., Milne, L., Hadoke, P. W. F., Handel, I. G., Péault, B., & Smith, L. B. (2019) · Scientific Reports · doi:10.1038/s41598-019-50855-0 · Cited by 10
Lam, Y. T., Hsu, C., Simpson, P. J. L., Dunn, L., Chow, R., Chan, K. H., Yong, A. S. C., Yu, Y. S., Sieveking, D. P., Lecce, L., et al. (2020) · Endocrinology · doi:10.1210/endocr/bqaa043 · Cited by 10
Primary and Secondary Hypogonadism in Male Persons with Diabetes Mellitus
Martins, J. M., Jorge, M. D. P., Maia, C. M., Roque, J., Lemos, C., Nunes, D., Reis, D., & Mota, C. (2021) · International Journal of Endocrinology · doi:10.1155/2021/8799537 · Cited by 11
Lee, J., Shah, P. H., Uma, D., Salvi, D. J., Rabbani, R., & Hamid, P. (2021) · Cureus · doi:10.7759/cureus.17475 · Cited by 10
Sex Hormones and Immunosenescence
Gómez, C. R., Nomellini, V., & Kovacs, E. J. (2019) · Springer eBooks · doi:10.1007/978-3-319-99375-1_42 · Cited by 10
Testosterone threshold – does one size fit all?
Maganty, A., Shoag, J. E., & Ramasamy, R. (2015) · The Aging Male · doi:10.3109/13685538.2015.1004047 · Cited by 10
Is it possible to prevent injurious falls?
Morley, J. E. (2014) · European Geriatric Medicine · doi:10.1016/j.eurger.2014.01.009 · Cited by 10
Deaths and Cardiovascular Events in Men Receiving Testosterone—Reply
Ho, P. M., Barón, A. E., & Wierman, M. E. (2014) · JAMA · doi:10.1001/jama.2014.401 · Cited by 10
Testosterone and male ageing: spinning the wheels
Handelsman, D. J. (2010) · The Medical Journal of Australia · doi:10.5694/j.1326-5377.2010.tb03961.x · Cited by 10
Zeng, B., Qiu, S., Xiong, X., Su, X., Zhang, Z., Wei, Q., & Yang, L. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1009900 · Cited by 9
Hypopituitarism and Cardiovascular Risk
Kraljević, I., Solak, M., Mandić, A., Kozamernik, K. M., Raičević, M., Divanović, A., Kovačević, Z., & Muzurović, E. M. (2025) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/10742484251332398 · Cited by 9
Glueck, C. J., Lee, K., Prince, M., Jetty, V., Shah, P. K., & Wang, P. (2016) · Journal of Investigative Medicine High Impact Case Reports · doi:10.1177/2324709616661833 · Cited by 9
Low Testosterone in Men with Cardiovascular Disease or Risk Factors: To Treat or Not To Treat?
Cassimatis, D. C., Crim, M. T., & WENGER, N. K. (2016) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-016-0496-0 · Cited by 9
Ischemic stroke and select adipose-derived and sex hormones: a review
Meadows, K. L. (2018) · HORMONES · doi:10.1007/s42000-018-0034-4 · Cited by 9
Liu, P., Wei, D., Nie, L., Fan, K., Xu, Q., Wang, L., Wang, J., Song, Y., Wang, M., Liu, X., et al. (2022) · Journal of Stroke and Cerebrovascular Diseases · doi:10.1016/j.jstrokecerebrovasdis.2022.106669 · Cited by 9
Zhang, L., Yang, F., Ma, J., Hu, Y., Li, M., Wang, C., Chang, X., & Yang, L. (2023) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2023.116 · Cited by 9
Circulating sex steroids and prostate cancer: introducing the time-dependency theory
Salonia, A., Abdollah, F., Umberto Capitanio, A., Suardi, N. R., Andrea Gallina, A., Castagna, G., Clementi, M. C., Briganti, A., Rigatti, P., & Montorsi, F. (2013) · World Journal of Urology · doi:10.1007/s00345-012-1009-8 · Cited by 9
Pagano, M. J., Fazio, A. D., Levy, A. C., RoyChoudhury, A., & Stahl, P. J. (2015) · Urology · doi:10.1016/j.urology.2015.12.030 · Cited by 9
Allameh, F., Pourmand, G., Bozorgi, A., Nekuie, S., & Namdari, F. (2016) · Europe PMC (PubMed Central) · Cited by 9
Nessighaoui, H., Geniaux, H., Dantoine, T., & Laroche, M. (2016) · Therapies · doi:10.1016/j.therap.2016.02.021 · Cited by 9
Approaches to male hypogonadism in primary care
Lawrence, K. L., Stewart, F., & Larson, B. M. (2017) · The Nurse Practitioner · doi:10.1097/01.npr.0000511774.51873.da · Cited by 9
Drew, W., Wilson, D. V., & Sapey, E. (2017) · Journal Of Aging Research And Healthcare · doi:10.14302/issn.2474-7785.jarh-17-1578 · Cited by 9
The Intersection of Medicine and Urology
Miner, M. M., Heidelbaugh, J. J., Paulos, M., Seftel, A. D., Jameson, J., & Kaplan, S. A. (2018) · Medical Clinics of North America · doi:10.1016/j.mcna.2017.11.002 · Cited by 9
How to Prevent Loss of Muscle Mass and Strength among Older People in Neuro-Rehabilitation?
Lathuilière, A., Mareschal, J., & Graf, C. E. (2019) · Nutrients · doi:10.3390/nu11040881 · Cited by 9
Effect of High Testosterone Levels on Endothelial Function in Aorta and Erectile Function in Rats
Kataoka, T., Fukamoto, A., Hotta, Y., Sanagawa, A., Maeda, Y., Furukawa‐Hibi, Y., & Kimura, K. (2022) · Sexual Medicine · doi:10.1016/j.esxm.2022.100550 · Cited by 9
Roth, M. Y. (2012) · The AMA Journal of Ethic · doi:10.1001/virtualmentor.2012.14.2.stas1-1202 · Cited by 9
Chmiel, A., Mizia‐Stec, K., Wierzbicka-Chmiel, J., Rychlik, S., Muras, A., Mizia, M., & Bienkowski, J. (2015) · Andrology · doi:10.1111/andr.12103 · Cited by 9
Current and emerging testosterone therapies for male hypogonadism
Kaminetsky, J. C., & Wynia, B. (2015) · Research and Reports in Endocrine Disorders · doi:10.2147/rred.s46193 · Cited by 9
Testosterone Deficiency Associated with Poor Glycemic Control in Korean Male Diabetics
Kim, J., Kim, B. S., Jeon, J. Y., Choi, Y. J., & Chung, Y. (2014) · Endocrinology and Metabolism · doi:10.3803/enm.2014.29.3.300 · Cited by 9
The appropriateness and persistence of testosterone replacement therapy in Ontario
Martins, D., Yao, Z., Tadrous, M., Shah, B. R., Juurlink, D. N., Mamdani, M., & Gomes, T. (2016) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.4083 · Cited by 9
Wallis, C. J. D., Saskin, R., Narod, S. A., Law, C., Kulkarni, G. S., Seth, A. K., & Nam, R. K. (2017) · British Journal of Urology · doi:10.1111/bju.13918 · Cited by 9
Clinical Update on Nursing Home Medicine: 2013
Messinger‐Rapport, B. J., Gammack, J. K., Thomas, D. R., & Morley, J. E. (2013) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2013.09.015 · Cited by 9
S-allyl Cysteine Enhances Testosterone Production in Mice and Mouse Testis-Derived I-10 Cells
Rana, M. M., Shiozawa, K., Mukai, K., Takayanagi, K., Eguchi, K., Sultana, H., Ohsaki, Y., Komai, M., & Shirakawa, H. (2021) · Molecules · doi:10.3390/molecules26061697 · Cited by 9
Advancements in pharmacotherapy for angina
Jain, A., Elgendy, I. Y., Al‐Ani, M. A., Agarwal, N., & Pepine, C. J. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1303483 · Cited by 9
Is Testosterone Replacement Safe in Men with Cardiovascular Disease?
Ahmed, T., Alattar, M., Pantalone, K. M., & Haque, R. U. (2020) · Cureus · doi:10.7759/cureus.7324 · Cited by 9
Wolfe, S. M. (2014) · BMJ · doi:10.1136/bmj.g1789 · Cited by 8
Khawcharoenporn, T., & Sha, B. E. (2016) · InTech eBooks · doi:10.5772/62390 · Cited by 9
Lee, H., Arai, I., & Kwon, S. (2024) · Nutrients · doi:10.3390/nu16050721 · Cited by 8
Wang, H., Zhou, Z., Liu, X., & Chen, Y. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2024.111966 · Cited by 8
Testosterone levels and heart failure in obese and non-obese men
Čulić, V., & Bušić, Ž. (2014) · International Journal of Cardiology · doi:10.1016/j.ijcard.2014.07.253 · Cited by 8
Update on the safety of testosterone therapy in cardiac disease
Aaronson, A. J., Morrissey, R. P., Nguyen, C. T., Willix, R., & Schwarz, E. R. (2011) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2011.566213 · Cited by 8
Androgen Therapy and Rehospitalization in Older Men With Testosterone Deficiency
Baillargeon, J., Deer, R., Kuo, Y., Zhang, D., Goodwin, J. S., & Volpi, E. (2016) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2016.03.016 · Cited by 8
The Endocrinology of Aging: A Key to Longevity “Great Expectations”
Reddy, S. S. K., & Chaiban, J. T. (2017) · Endocrine Practice · doi:10.4158/ep171793.ra · Cited by 9
The implications of hyperoxia, type 1 diabetes and sex on cardiovascular physiology in mice
Bojkovic, K., Rodgers, J. L., Vichare, R., Nandi, A., Mansour, N., Saleem, F., Abıdın, Z. U., Vanthenapalli, S., Cheng, F., & Panguluri, S. K. (2021) · Scientific Reports · doi:10.1038/s41598-021-02550-2 · Cited by 8
Metadata
- Authors
- Basaria, S., Coviello, A. D., Travison, T. G., Storer, T. W., Farwell, W. R., Jette, A. M., Eder, R., Tennstedt, S., Ulloor, J., Zhang, A., Choong, K., Lakshman, K. M., Mazer, N. A., Miciek, R., Krasnoff, J., Elmi, A., Knapp, P. E., Brooks, B., Appleman, E., Aggarwal, S., Bhasin, G., Hede-Brierley, L., Bhatia, A., Collins, L., LeBrasseur, N., Fiore, L. D., & Bhasin, S.
- Affiliations
- Boston University (US)
- Brigham and Women's Hospital (US)
- New England Research Institutes (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2010-07-08
- Volume
- 363
- Issue
- 2
- Pages
- 109-122
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC3440621
- OpenAlex
- W2155877918
- Cited by
- 1,494
- References
- 56
- Citations by year
- 2026: 33 · 2025: 52 · 2024: 68 · 2023: 63 · 2022: 76 · 2021: 66 · 2020: 91 · 2019: 65 · 2018: 92 · 2017: 132 · 2016: 103 · 2015: 122 · 2014: 169 · 2013: 96 · 2012: 108
- FWCI
- 85.68
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- U.S. Department of Veterans Affairs
- National Institutes of Health (5p30ag031679-15)
- National Institute on Aging (U01AG014369, R01AG037193, 5 P30 AG031679, P30-AG031679, 1UO1AG14369)
- National Center for Research Resources (UL1RR025771)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Keywords
- testosterone replacement therapy, testosterone gel, adverse events, cardiovascular events, older men, mobility limitations, hypogonadism, muscle strength, trial discontinuation, drug safety
- MeSH terms
- Administration, Cutaneous, Aged, Aged, 80 and over, Cardiovascular Diseases, Double-Blind Method, Exercise Test, Gels, Humans, Hyperlipidemias, Hypertension, Male, Obesity, Risk Factors, Testosterone, Logistic Models, Walking, Kaplan-Meier Estimate, Muscle Strength
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
